NCT06645522View on ClinicalTrials.gov

Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

October 30, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

January 30, 2027

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Edaravone dexborneol

Edaravone dexborneol injection 37.5mg (edaravone 30mg and dexborneol 7.5mg) and 100ml of 0.9% saline every 12 hours for 7 days; sequentially a sublingual dose of edaravone dexborneol 36 mg (edaravone, 30 mg; dexborneol, 6 mg) twice a day for 21 days.

DRUG

Placebo

Placebo injection every 12 hours for 7 days; sequentially a sublingual dose of placebo drug twice a day for 21 days.

Trial Locations (1)

130000

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Yi Yang

OTHER

NCT06645522 - Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter